Integral Health Asset Management’s Gossamer Bio GOSS Stock Holding History

Integral Health Asset Management’s Portfolio GOSS Stock Details GOSS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,000,000	Closed	-$3.1M	–	100
2025 Q4	$3.1M	Buy	+1,000,000	New	+$2.85M	0.15%	80
2022 Q4	–	Sell	-300,000	Closed	-$3.59M	–	76
2022 Q3	$3.59M	Buy	+300,000	New	+$3.72M	0.7%	48
2020 Q4	–	Sell	-200,000	Closed	-$2.48M	–	71
2020 Q3	$2.48M	Sell	200,000 -70,000	-26%	-$928K	0.76%	49
2020 Q2	$3.51M	Buy	+270,000	New	+$3.4M	1.05%	39
2020 Q1	–	Sell	-60,000	Closed	-$938K	–	64
2019 Q4	$938K	Buy	+60,000	New	+$1.21M	0.37%	49

Other funds holding GOSS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kalehua Capital Management Dallas, Texas $174M AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Integral Health Asset Management's GOSS Position: Q1 2026 in Review

Integral Health Asset Management sold out of Gossamer Bio (GOSS) in Q1 2026, closing a stake of 1,000,000 shares — an estimated $3.1M sold.

Integral Health Asset Management first reported a position in GOSS in Q4 2019 and held it in 5 quarters. The position peaked at $3.59M in Q3 2022. 185 funds tracked by Wall St. Rank hold GOSS as of Q1 2026.

Integral Health Asset Management reported no remaining Gossamer Bio position as of Q1 2026 after selling out during the quarter.
Integral Health Asset Management sold 1,000,000 Gossamer Bio shares in Q1 2026, an estimated $3.1M.
Integral Health Asset Management first reported a position in Gossamer Bio in Q4 2019 and held it in 5 quarters.
Integral Health Asset Management's Gossamer Bio position peaked at $3.59M in Q3 2022.
185 funds tracked by Wall St. Rank held Gossamer Bio as of Q1 2026.

Based on Integral Health Asset Management's 13F filing for Q1 2026, filed 15 May 2026.